Video description ranks anti-ageing papers from 1996 to 2025
The description presents a bibliometric ranking of anti-ageing and geroscience publications from 1996 to the end of 2025, scored by citations, field-weighted citation impact, alignment with the Hallmarks of Aging and progression into Phase II/III human longevity trials. [1]
Automatic summary · not editorially reviewed
The key findings
The described report divides anti-ageing research from 1996 to 2025 into three eras, from longevity genes in C. elegans to epigenetic clocks and partial reprogramming. [1]
The ranking is described as using field-weighted citation impact, alignment with the Hallmarks of Aging and progression into Phase II/III human longevity trials, not citation counts alone. [1]
The description presents the compilation as a strategic resource for gerontologists, biotech investors and academic researchers. [1]
The source at a glance
- Study type / format
- Video description of a bibliometric ranking report
- Population / context
- Scholarly publications on anti-ageing and geroscience from 1996 to the end of 2025, as described in the video description.
- Summary based on
- Creator description
- Original publication
- June 1, 2026
Three eras in the described ranking
According to the description, the report divides three decades into three eras. The first, 1996–2005, covers sirtuin biology, the first longevity genes found in C. elegans, and calorie restriction research on insulin/IGF-1 signalling. The second, 2006–2015, covers the Hallmarks of Aging, cellular reprogramming with Yamanaka factors and the first senolytics. The third, 2016–2025, covers epigenetic clocks, partial reprogramming and what the description calls 2025 breakthroughs in AI-orchestrated personalised longevity interventions and lysosomal restoration.
Supporting source [1]
Metrics described for scoring publications
The description says the ranking goes beyond raw citation counts. It also uses Field-Weighted Citation Impact, a measure of how often a paper is cited relative to its field, Hallmark Integration Velocity, described as alignment with the Hallmarks of Aging framework, and a Clinical Translation Index, described as progression into Phase II/III human longevity trials. The description frames the overall shift as moving from palliative geriatric care toward preventative, regenerative and longevity-focused molecular medicine.
Supporting source [1]
Audience and scope stated in the description
The description calls the compilation a strategic resource for gerontologists, biotech investors and academic researchers, meant to identify cornerstone publications on human healthspan. It does not report how many papers were ranked, which specific papers topped the list, or how the three metrics were weighted. It also gives no results from human trials; the Phase II/III trials appear only as a scoring criterion. The description does not establish that ageing is reversible in humans.
Supporting source [1]
How to interpret this
Only the video description was reviewed; the video and transcript were not reviewed. The description gives no number of ranked papers, no named top-ranked papers, no metric weightings and no human trial results. Claims about reversibility and 2025 breakthroughs are the creator's framing, not established findings.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
Global Impact Focus · youtube.com · June 1, 2026